Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
...
Health Technology » Pharmaceuticals Other
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMRN | Amarin Corp. Plc | 11.77% | 24.02 | 1.7% | $252.26m | |
| VRX | Valeant Pharmaceuticals International, Inc. | 2.63% | 28.48 | 14.1% | $167.58m | |
| BHC | Bausch Health Cos., Inc. | 2.63% | 28.48 | 0.0% | $119.07m | |
| GWPH | GW Pharmaceuticals Plc | 2.26% | 108.41 | 6.2% | $82.69m | |
| MDCO | The Medicines Co. | 2.14% | 51.98 | 20.2% | $80.72m | |
| JAZZ | Jazz Pharmaceuticals Plc | 3.60% | 138.64 | 2.3% | $64.51m | |
| SAGE | SAGE Therapeutics, Inc. | 3.93% | 146.32 | 8.6% | $52.92m | |
| PRGO | Perrigo Co. Plc | 2.83% | 49.40 | 6.8% | $50.04m | |
| ENDP | Endo International Plc | 8.89% | 4.53 | 8.8% | $45.54m | |
| UTHR | United Therapeutics Corp. | 1.01% | 90.43 | 14.3% | $39.52m | |
| HZNP | Horizon Therapeutics Plc | 1.51% | 30.26 | 6.6% | $38.93m | |
| ICPT | Intercept Pharmaceuticals, Inc. | -0.96% | 82.25 | 16.9% | $38.81m | |
| ICLR | ICON plc | 1.42% | 154.59 | 4.2% | $37.69m | |
| CTLT | Catalent, Inc. | 2.65% | 50.41 | 2.4% | $31.87m | |
| ARGX | argenx SE | 1.45% | 139.37 | 0.0% | $26.47m |
Company Profile
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.